GENEVA—The use of combinations including checkpoint inhibition with other immunotherapies, other targeted therapies and chemotherapy was discussed at the European Lung Cancer Conference by Martin Reck MD PhD from the department of thoracic oncology...
GENEVA—The recent success of treatment with immune checkpoint inhibitors suggests that immunotherapy could presently move center stage to play a leading role in fighting non-small cell lung cancer—the European Lung Cancer Conference heard from...
GENEVA—Evidence presented at the 2015 European Lung Cancer conference from the large SQUIRE multicenter open label study points to the fact that older patients with squamous non small cell lung cancer can benefit from a three drug regimen including...
GENEVA—Toxicities from targeted agents used in lung cancer differ from those encountered with other drugs but can be managed successfully if recognized early and treated. At the European Lung Cancer Conference, Silvia Novello MD, PhD, an Assistant...
GENEVA—The potential for using vaccines as important weapons against non small cell lung cancer has not yet been realized according to Johan Vansteenkiste MD PhD, an oncologist and professor of medicine at University Hospitals Leuven in Belgium...
VIENNA—Three key targetable pathways for breast cancer treatment were assessed at the St Gallen Breast Cancer Conference by Clifford Hudis, MD, Chief of the Breast Medicine Service at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical...
VIENNA—Obesity and insulin resistance were named as important targets for primary prevention of breast cancer by Pamela J. Goodwin, MD, MSc, FRCPC, Professor of Medicine and Director of the Marvelle Koffler Breast Centre at the University of...
VIENNA—The bone microenvironment was regarded as a worthy target for breast cancer treatment in comments at the St Gallen Breast Cancer Conference from Michael Gnant MD, a Professor and Director of the Medical University of Vienna, who gave Oncology...
VIENNA—At the St Gallen Breast Cancer Conference BCL-2 was named as a therapeutic target for patients with hormone-receptor positive breast cancer by Geoffrey J Lindeman BSc(Med) PhD, from the University of Melbourne and the Walter and Eliza Hall...
VIENNA—Because harnessing the immune system is now proven as a way of managing breast cancer, clinicians should consider the role of tumor infiltrating lymphocytes, according to Giuseppe Curigliano MD PhD, Director of the Early Drug Development for...
VIENNA—Understanding the emerging genomic landscape of breast cancer needed international research including large molecular screening projects—according to Peter Campbell MD PhD, head of Cancer Genetics and Genomics at the Sanger Institute in...
VIENNA—With actionable genomic alterations already being targeted by some existing approved drugs in patients with breast cancer genomic analysis was being hailed at the St Gallen Breast Cancer Conference as a way to expand the range of...